PYC Therapeutics (PYC) Q1 2027 earnings summary

Executive summary

• Four investigational programs advanced toward near-term objectives in Q3 CY26; three are in clinical development and PMS progressed into IND-enabling studies.

• The pipeline targets genetic diseases linked to insufficient gene expression; PMS is expected to enter human trials in 2027, subject to regulatory alignment and stated risks.

Financial highlights

• Q3 operating cash outflow was $14.859m, including $21.370m of R&D payments; interest received was $8.054m.

• At 30 September 2026, cash and treasury investments totaled $655m: $16.820m cash, $200m term deposits and $438m financial assets.

• Net investing cash outflow was $21.768m; net financing cash inflow was $65k, including $170k equity proceeds and $105k lease repayments.

Outlook and guidance

• PKD repeat-dose and open-label extension studies are progressing toward clinical proof of mechanism and concept; data are expected in CY27.

• PMS first-in-human studies are expected in 2027 following completion of GLP toxicology studies, subject to regulatory alignment and stated risks.

• ADOA safety and efficacy outcomes are expected in CY27; RP11 long-term Phase 1/2 data will inform a potential registrational study, with preparation for a possible 2027 start.

• Funding is expected to support development of all four programs through CY2030, subject to stated risks and uncertainties.